Refine
Has Fulltext
- yes (140)
Is part of the Bibliography
- yes (140)
Year of publication
Document Type
- Journal article (119)
- Preprint (9)
- Review (9)
- Conference Proceeding (1)
- Other (1)
- Working Paper (1)
Keywords
- metabolism (8)
- apoptosis (6)
- cosmology (6)
- crystallization (6)
- SARS-CoV-2 (5)
- cytokinins (5)
- qubit (5)
- COVID-19 (4)
- decoherence (4)
- evolution (4)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (138)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (6)
- Institut für Molekulare Infektionsbiologie (5)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (5)
- Center for Computational and Theoretical Biology (4)
- Institut für Experimentelle Biomedizin (4)
- Institut für Pharmakologie und Toxikologie (4)
- Institut für Virologie und Immunbiologie (4)
- Kinderklinik und Poliklinik (3)
- Institut für Humangenetik (2)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 031A408B (1)
- CoG 721016–HERPES (1)
- ESF-ZDEX 4.0 (1)
After a large outbreak in Brazil, novel drugs against Zika virus became extremely necessary. Evaluation of virus-based pharmacological strategies concerning essential host factors brought us to the idea that targeting the Axl receptor by blocking its dimerization function could be critical for virus entry. Starting from experimentally validated compounds, such as RU-301, RU-302, warfarin, and R428, we identified a novel compound 2′ (R428 derivative) to be the most potent for this task amongst a number of alternative compounds and leads. The improved affinity of compound 2′ was confirmed by molecular docking as well as molecular dynamics simulation techniques using implicit solvation models. The current study summarizes a new possibility for inhibition of the Axl function as a potential target for future antiviral therapies.